Insider Selling: Elanco Animal Health (NYSE:ELAN) Insider Sells $100,050.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Timothy Bettington sold 4,350 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the sale, the insider directly owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $22.52 on Thursday. The firm has a market capitalization of $11.25 billion, a PE ratio of -54.94, a P/E/G ratio of 2.01 and a beta of 1.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The business has a 50-day moving average of $23.25 and a two-hundred day moving average of $23.57. Elanco Animal Health Incorporated has a 12 month low of $19.40 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Institutional Trading of Elanco Animal Health

Hedge funds have recently bought and sold shares of the stock. Sapient Capital LLC increased its position in shares of Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after purchasing an additional 420 shares during the period. Farther Finance Advisors LLC lifted its position in Elanco Animal Health by 12.5% in the third quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock worth $94,000 after purchasing an additional 464 shares during the period. Bessemer Group Inc. lifted its position in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the period. Fifth Third Wealth Advisors LLC lifted its position in Elanco Animal Health by 4.2% in the first quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock worth $342,000 after purchasing an additional 579 shares during the period. Finally, Nisa Investment Advisors LLC boosted its stake in Elanco Animal Health by 3.4% during the third quarter. Nisa Investment Advisors LLC now owns 19,749 shares of the company’s stock worth $442,000 after buying an additional 654 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent research reports. Jefferies Financial Group cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating and reduced their price target for the company from $31.00 to $24.00 in a research report on Tuesday. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.42.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.